arthyperАртериальная гипертензия"Arterial’naya Gipertenziya" ("Arterial Hypertension")1607-419X2411-8524Antihypertensive League10.18705/1607-419X-2014-20-1-27-33arthyper-40Research ArticleРЕКОМЕНДАЦИИGUIDELINESНОВОЕ В ТЕРАПЕВТИЧЕСКИХ СТРАТЕГИЯХNOVEL THERAPEUTIC STRATEGIESКотовскаяЮ. В.KotovskayaY. V.

Доктор медицинских наук, профессор кафедры пропедевтики внутренних болезней ФГБОУ ВПО «Российский университет дружбы народов» Минобрнауки России (РУДН)? Контактная информация: Городская клиническая больница № 64, кафедра пропедевтики внутренних болезней ФГБОУ ВПО «Российский университет дружбы народов» Минобрнауки России, ул. Вавилова, д. 61, Москва, Россия, 117292. E-mail: kotovskaya@bk.ru (Котовская Юлия Викторовна).

Corresponding author: Clinical Hospital № 64, the Department of Internal Diseases Propaedeutics at Russian People’s Friendship University, 61 Vavilov st., Moscow, Russia, 117292., E-mail: kotovskaya@bk.ru (Julia V. Kotovskaya, MD, PhD, Professor at the Department of Internal Diseases Propaedeutics at Russian People’s Friendship University).

kotovskaya@bk.ruКравцоваО. А.KravtsovaO. V.

Аспирант кафедры пропедевтики внутренних болезней РУДН

kotovskaya@bk.ruПавловаЕ. А.PavlovaE. A.

Ассистент кафедры пропедевтики внутренних болезней РУДН

kotovskaya@bk.ruРоссийский университет дружбы народов, МоскваРоссияRussian People’s Friendship University, MoscowRussian Federation2014270220152012733Copyright © Котовская Ю.В., Кравцова О.А., Павлова Е.А., 20152015Котовская Ю.В., Кравцова О.А., Павлова Е.А.Kotovskaya Y.V., Kravtsova O.V., Pavlova E.A.This work is licensed under a Creative Commons Attribution 4.0 License.https://htn.almazovcentre.ru/jour/article/view/40

В статье обсуждаются основные принципиальные изменения терапевтических стратегий в рекомендациях европейских обществ по артериальной гипертензии 2013 года, рассматриваются особенности подхода к терапии отдельных категорий больных — пациентов с сердечно-сосудистыми заболеваниями, сахарным диабетом и хронической болезнью почек, лиц пожилого возраста? обсуждаются преимущества более консервативной тактики лечения. 

The article reviews the main changes in therapeutic approaches for hypertension management according to the European guidelines 2013, in particular, special conditions are discussed, including patients with cardiovascular diseases, diabetes mellitus, chronic kidney disease, elderly population? the advantages of less aggressive approach are discussed.

особые группы больныхкомбинированная терапиявысокий сердечно-сосудистый рискрекомендациимонотерапияReferencesMancia G., De Backer G., Dominiczak A., Cifkova R., Fagard R., Germano G. et al. The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and the European Society of Cardiology (ESC). 2007 Guidelines for the management of arterial hypertension // J. Hypertens. — 2007. — Vol. 25, № 9. — P. 1105–1187.Mancia G., De Backer G., Dominiczak A., Cifkova R., Fagard R., Germano G. et al. The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and the European Society of Cardiology (ESC). 2007 Guidelines for the management of arterial hypertension // J. Hypertens. — 2007. — Vol. 25, № 9. — P. 1105–1187.Mancia G., Fagard R., Narkiewicz R., Redon J., Zanchetti A., Bohm M et al. The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and the European Society of Cardiology (ESC). 2013 ESH/ESC Guidelines for the management of arterial hypertension // J. Hypertens. — 2013. — Vol. 31, № 7. — P. 1281–1357.Mancia G., Fagard R., Narkiewicz R., Redon J., Zanchetti A., Bohm M et al. The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and the European Society of Cardiology (ESC). 2013 ESH/ESC Guidelines for the management of arterial hypertension // J. Hypertens. — 2013. — Vol. 31, № 7. — P. 1281–1357.Schrier R.W., Estacio R.O., Esler A., Mehler P. Effects of aggressive blood pressure control in normotensive type 2 diabetic patients on albuminuria, retinopathy and strokes // Kidney Int. — 2002. — Vol. 61, № 3. — P. 1086–1097.Schrier R.W., Estacio R.O., Esler A., Mehler P. Effects of aggressive blood pressure control in normotensive type 2 diabetic patients on albuminuria, retinopathy and strokes // Kidney Int. — 2002. — Vol. 61, № 3. — P. 1086–1097.PATS Collaborating Group. Poststroke antihypertensive treatment study. A preliminary result // Chin. Med. J. (Engl). — 1995. — Vol. 108, № 9. — P. 710–717.PATS Collaborating Group. Poststroke antihypertensive treatment study. A preliminary result // Chin. Med. J. (Engl). — 1995. — Vol. 108, № 9. — P. 710–717.Arima H., Chalmers J., Woodward M., Anderson C., Rodgers A., Davis S. et al. Lower target blood pressures are safe and effective for the prevention of recurrent stroke: the PROGRESS trial // J. Hypertens. — 2006. — Vol. 24, № 6. — P. 1201–1208.Arima H., Chalmers J., Woodward M., Anderson C., Rodgers A., Davis S. et al. Lower target blood pressures are safe and effective for the prevention of recurrent stroke: the PROGRESS trial // J. Hypertens. — 2006. — Vol. 24, № 6. — P. 1201–1208.Zanchetti A., Grassi G., Mancia G. When should antihypertensive drug treatment be initiated and to what levels should systolic blood pressure be lowered? A critical re-appraisal // J. Hypertens. — 2009. — Vol. 27, № 5. — P. 923–934.Zanchetti A., Grassi G., Mancia G. When should antihypertensive drug treatment be initiated and to what levels should systolic blood pressure be lowered? A critical re-appraisal // J. Hypertens. — 2009. — Vol. 27, № 5. — P. 923–934.Sipahi I., Swamiinathan A., Natesan V., Debanne S.M., Simon D.I., Fang J.C. Effect of antihypertensive therapy on incident stroke in cohorts with prehypertensive blood pressure levels: a meta-analysis of randomized controlled trials // Stroke. — 2012. — Vol. 43, № 2. — P. 432–440.Sipahi I., Swamiinathan A., Natesan V., Debanne S.M., Simon D.I., Fang J.C. Effect of antihypertensive therapy on incident stroke in cohorts with prehypertensive blood pressure levels: a meta-analysis of randomized controlled trials // Stroke. — 2012. — Vol. 43, № 2. — P. 432–440.Julius S., Nesbitt S.D., Egan B.M., Weber M.A., Michelson E.L., Karioti N. et al. Feasibility of treating prehypertension with an angiotensin receptor blocker // N. Engl. J. Med. 2006. — Vol. 354, № 16. — P. 1685–1697.Julius S., Nesbitt S.D., Egan B.M., Weber M.A., Michelson E.L., Karioti N. et al. Feasibility of treating prehypertension with an angiotensin receptor blocker // N. Engl. J. Med. 2006. — Vol. 354, № 16. — P. 1685–1697.DREAM Trial Investigators. Effects of ramipril and rosiglitazone on cardiovascular and renal outcomes in people with impaired glucose tolerance or impaired fasting glucose: results of the Diabetes REduction Assessment with ramipril and rosiglitazone Medication (DREAM) trial // Diabetes Care. — 2008. — Vol. 31, № 8. — P. 1007–1014.DREAM Trial Investigators. Effects of ramipril and rosiglitazone on cardiovascular and renal outcomes in people with impaired glucose tolerance or impaired fasting glucose: results of the Diabetes REduction Assessment with ramipril and rosiglitazone Medication (DREAM) trial // Diabetes Care. — 2008. — Vol. 31, № 8. — P. 1007–1014.The NAVIGATOR study Group. Effect of valsartan on the incidence of diabetes and cardiovascular events // N. Eng. J. Med. — 2010. — Vol. 362, № 16. — P. 1477–1490.The NAVIGATOR study Group. Effect of valsartan on the incidence of diabetes and cardiovascular events // N. Eng. J. Med. — 2010. — Vol. 362, № 16. — P. 1477–1490.Haller H., Ito S., Izzo J.L., Januszewicz A., Katayama S., Menne J. et al., ROADMAP Trial Investigators. Olmesartan for the delay or prevention of microalbuminuria in type 2 diabetes // N. Engl. J. Med. — 2011. — Vol. 364, № 10. — P. 907–917.Haller H., Ito S., Izzo J.L., Januszewicz A., Katayama S., Menne J. et al., ROADMAP Trial Investigators. Olmesartan for the delay or prevention of microalbuminuria in type 2 diabetes // N. Engl. J. Med. — 2011. — Vol. 364, № 10. — P. 907–917.Mann J.F., Schmieder R.E., McQueen M., Dyal L., Schumacher H., Pogue J. et al. Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial // Lancet. — 2008. — Vol. 372, № 9638. — P. 547–553.Mann J.F., Schmieder R.E., McQueen M., Dyal L., Schumacher H., Pogue J. et al. Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial // Lancet. — 2008. — Vol. 372, № 9638. — P. 547–553.Bakris G.L., Seraidis P.A., Weir M.R., Dalhof B., Pitt B., Jamerson K. et al., ACCOMPLISH Trial Investigators. Renal outcomes with different ixed-dose combination therapies in patients with hypertension at high risk for cardiovascular events (ACCOM-PLISH): a prespeciied secondary analysis of randomised controlled trial // Lancet. — 2010. — Vol. 375, № 9721. — P. 1173–1181.Bakris G.L., Seraidis P.A., Weir M.R., Dalhof B., Pitt B., Jamerson K. et al., ACCOMPLISH Trial Investigators. Renal outcomes with different ixed-dose combination therapies in patients with hypertension at high risk for cardiovascular events (ACCOM-PLISH): a prespeciied secondary analysis of randomised controlled trial // Lancet. — 2010. — Vol. 375, № 9721. — P. 1173–1181.Costanzo P., Perrone-Filardi P., Vassallo E., Paolillo S., Cesarano P., Brevetti G., Chiariello M. Does carotid intima-media thickness regression predict reduction of cardiovascular events? A meta-analysis of 41 randomized trials // J. Am. Coll. Cardiol. 2010. — Vol. 56, № 24. — P. 2006–2020.Costanzo P., Perrone-Filardi P., Vassallo E., Paolillo S., Cesarano P., Brevetti G., Chiariello M. Does carotid intima-media thickness regression predict reduction of cardiovascular events? A meta-analysis of 41 randomized trials // J. Am. Coll. Cardiol. 2010. — Vol. 56, № 24. — P. 2006–2020.Goldberger Z.D., Valle J.A., Dandekar V.K., Chan P.S., Ko D.T., Nallamothu B.K. Are changes in carotid intima-media thickness related to risk of nonfatal myocardial infarction? A critical review and meta-regression analysis // Am. Heart. J. — 2010. — Vol. 160, № 4. — P. 701–714.Goldberger Z.D., Valle J.A., Dandekar V.K., Chan P.S., Ko D.T., Nallamothu B.K. Are changes in carotid intima-media thickness related to risk of nonfatal myocardial infarction? A critical review and meta-regression analysis // Am. Heart. J. — 2010. — Vol. 160, № 4. — P. 701–714.

The authors declare that there are no conflicts of interest present.